No quarterly revenue total was found in CLIMB BIO, INC.'s SEC filings.
Climb Bio, Inc. (CLYM) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$10.8 million. As of Jun 30, 2026 it held $239.2 million in cash and investments and $1.3 million in total debt.
Revenue
—
Net income
$-13.50M
-55.8% vs year-ago quarter
Operating cash flow
$-10.55M
+5.4% vs year-ago quarter
Free cash flow
$-10.81M
+3.7% vs year-ago quarter
EPS
$-0.18
-38.5% vs year-ago quarter
Dividend per share
None
Shares outstanding
57.44M
-15.2% vs year-ago quarter
Net cash
$237.91M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CLYM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Wellesley Hills, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1768446
- Former names
- Eliem Therapeutics, Inc. (until Sep 20, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$15.4M | -$15.2M | -$19.3M | -$14.9M | -$10.7M |
| Net income | -$13.5M | -$13.7M | -$17.5M | -$12.9M | -$8.7M |
| Diluted EPS | -$0.18 | -$0.20 | -$0.26 | -$0.19 | -$0.13 |
| Operating cash flow | -$10.5M | -$14.4M | -$15.6M | -$12.1M | -$11.1M |
| Free cash flow | -$10.8M | — | -$15.6M | -$12.2M | -$11.2M |
| Total assets | $246.3M | $152.4M | $167.7M | $182.3M | $192.4M |
| Total liabilities | $6.7M | $4.3M | $7.3M | $5.3M | $6.6M |
| Stockholders' equity | $239.5M | $148.1M | $160.5M | $177.0M | $185.8M |
| Cash and investments | $239.2M | $146.3M | $160.7M | $175.8M | $187.4M |
| Total debt | $1.3M | $479,000 | $541,000 | $580,000 | $639,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 26, 2026 | Oct 24, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 23, 2026 | Oct 23, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 3, 2026 | Sep 3, 2026 |
| 8-K |
Current report
Other events
|
Aug 14, 2026 | Aug 13, 2026 |
All 323 Climb Bio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.